IP Library Assignment 068086/0538
Patent Assignment
Reel/Frame 068086/0538

Security Interest

Recorded: 2024-07-25 Pages: 12
Assignor
EFFECTOR THERAPEUTICS, INC.
Executed: 2024-07-25
Assignee
OXFORD FINANCE LLC, AS COLLATERAL AGENT
115 SOUTH UNION ST, SUITE 300, ALEXANDRIA, VIRGINIA, 22314
Covered Properties (30)
Use of Translational Profiling to Identify Target Molecules for Therapeutic Treatment
Application: 14/176,018 →
Publication: US 2014/0288097
Mnk Biomarkers and Uses Thereof
Application: 16/881,193 →
Publication: US 2021/0010086
EIF4A Inhibitor Combinations
Application: 17/210,062 →
Publication: US 2021/0299111
EIF4E-Inhibiting Compounds and Methods
Application: 17/587,185 →
Publication: US 2023/0108594
EIF4A-Inhibiting Compounds and Methods Related Thereto
Application: 17/720,529 →
Publication: US 2023/0071483
Methods and Compositions for Cellular Immunotherapy
Application: 18/158,770 →
Publication: US 2023/0381232
EIF4A-Inhibiting Compounds and Methods Related Thereto
Application: 18/324,616 →
Publication: US 2023/0295179
Solid Forms of an eIF4E Inhibitor
Application: 18/268,795 →
Publication: US 2024/0076301
Methods of Treating Braf-Mutated Cancer Cells
Application: 17/624,504 →
Publication: US 2022/0378821
Compositions and Methods for Treating Fibrotic Disease
Patent: 9,993,494 →
Application: 14/616,690 →
Publication: US 2015/0224132
Mnk Inhibitors and Methods Related Thereto
Patent: 9,382,248 →
Application: 14/748,990 →
Publication: US 2015/0376181
Inhibitors of Immune Checkpoint Modulators and Related Methods
Application: 15/130,538 →
Publication: US 2016/0303124
Mnk Inhibitors and Methods Related Thereto
Patent: 9,669,031 →
Application: 15/187,854 →
Publication: US 2016/0317536
Isoindoline, Azaisoindoline, Dihydroindenone and Dihydroazaindenone Inhibitors of MNK1 and MNK2
Application: 15/337,184 →
Publication: US 2017/0121346
Heterocyclic Compounds That Inhibit the Kinase Activity of Mnk Useful for Treating Various Cancers
Application: 15/355,271 →
Publication: US 2017/0145009
EIF4A-Inhibiting Compounds and Methods Related Thereto
Patent: 9,957,277 →
Application: 15/358,761 →
Publication: US 2017/0145026
Mnk Inhibitors and Methods Related Thereto
Patent: 9,814,718 →
Application: 15/611,966 →
Publication: US 2017/0266185
EIF4A-Inhibiting Compounds and Methods Related Thereto
Application: 15/917,973 →
Publication: US 2018/0298017
Compositions and Methods for Treating Fibrotic Disease
Application: 15/973,281 →
Publication: US 2019/0038657
Methods and Compositions for Cellular Immunotherapy
Application: 15/989,098 →
Publication: US 2018/0353545
Benzimidazole-Indole Inhibitors of MNK1 and MNK2
Application: 16/162,459 →
Publication: US 2019/0119256
Piperidine-Substituted Mnk Inhibitors and Methods Related Thereto
Application: 16/233,507 →
Publication: US 2019/0275039
Pyrrolo-, Pyrazolo-, Imidazo-Pyrimidine and Pyridine Compounds That Inhibit MNK1 and MNK2
Application: 16/378,809 →
Publication: US 2019/0330216
Compositions and Methods for an Improved Antitumor Immune Response
Application: 16/616,087 →
Publication: US 2020/0147135
Crystalline Forms of Mnk Inhibitors
Application: 16/661,507 →
Publication: US 2020/0131179
EIF4A-Inhibiting Compounds and Methods Related Thereto
Application: 16/804,937 →
Publication: US 2020/0339590
Methods and Compositions for Cellular Immunotherapy
Application: 17/025,607 →
Publication: US 2021/0177898
Piperidine-Substituted Mnk Inhibitors and Methods Related Thereto
Application: 17/396,187 →
Publication: US 2022/0096472
Crystalline Forms of Mnk Inhibitors
Application: 17/484,564 →
Publication: US 2022/0119387
EIF4E-Inhibiting Compounds and Methods
Application: 16/916,820 →
Related Assignments (10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 21, 2014
From: APPLEMAN, JAMES; WORLAND, STEVE
To: EFFECTOR THERAPEUTICS, INC.
Reel/Frame 034228/0778 →
Assignment of Assignor's Interest Nov 21, 2014
From: RUGGERO, DAVIDE; HSIEH, ANDREW; EDLIND, MERRITT; SHOKAT, KEVAN M.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 034228/0661 →
Assignment of Assignor's Interest Sep 4, 2015
From: REICH, SIEGFRIED H.; SPRENGELER, PAUL A.; XIANG, ALAN X.; ERNST, JUSTIN T.
To: EFFECTOR THERAPEUTICS, INC.
Reel/Frame 036496/0568 →
Assignment of Assignor's Interest Jul 1, 2016
From: WEBSTER, KEVIN R.; GOEL, VIKAS
To: EFFECTOR THERAPEUTICS, INC.
Reel/Frame 039064/0369 →
Assignment of Assignor's Interest Nov 16, 2016
From: APPLEMAN, JAMES; THOMPSON, PEGGY A.
To: EFFECTOR THERAPEUTICS, INC.
Reel/Frame 040347/0895 →
Confirmatory License Mar 17, 2017
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042038/0895 →
Assignment of Assignor's Interest Jan 22, 2018
From: ERNST, JUSTIN T.; REICH, SIEGFRIED H.; SPRENGELER, PAUL A.; TRAN, CHINH VIET
To: EFFECTOR THERAPEUTICS, INC.
Reel/Frame 045108/0821 →
Assignment of Assignor's Interest Feb 19, 2026
From: OXFORD FINANCE LLC; EFFECTOR THERAPEUTICS, INC.
To: SJP BIOTEC GMBH
Reel/Frame 074939/0717 →
Assignment of Assignor's Interest Feb 20, 2026
From: OXFORD FINANCE LLC; EFFECTOR THERAPEUTICS, INC.
To: SJP BIOTEC GMBH
Reel/Frame 074946/0177 →
Assignment of Assignor's Interest Feb 26, 2026
From: ERNST, JUSTIN T.; REICH, SIEGFRIED H.; SPRENGELER, PAUL A.; TRAN, CHINH VIET
To: EFFECTOR THERAPEUTICS, INC.
Reel/Frame 073902/0270 →